methyl 3-[3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)phenyl]propionate | 500794-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-[3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)phenyl]propionate
• 英文别名: Methyl-3-[3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)phenyl]propionate；methyl 3-[3,5-dibromo-4-(3-iodo-4-methoxy-5-propan-2-ylphenoxy)phenyl]propanoate
• CAS: 500794-86-5
• 化学式: C₂₀H₂₁Br₂IO₄
• 分子量: 612.097
• InChiKey: KOCNBEZRKJKTSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-[3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)phenyl]propionate 在 palladium diacetate 、 三氟二甲基硫醚络合物 、 N,N-二异丙基乙胺 、 lithium chloride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 3-{3,5-dibromo-4-[4-hydroxy-3-isopropyl-5-((E)-2-pyridin-4-yl-vinyl)phenoxy]phenyl}propionate
  参考文献：
  名称：

  Thyroid Receptor Ligands. 6. A High Affinity “Direct Antagonist” Selective for the Thyroid Hormone Receptor

  摘要：

  A new high-affinity thyroid hormone antagonist 6 with druglike properties was designed and synthesized. The compound behaved as an antagonist in a cell transactivation assay, and in a first in vivo experiment in rats.

  DOI：

  10.1021/jm060521i
• 作为产物：
  描述：

  methyl 3-[3,5-dibromo-4-(3-amino-5-isopropyl-4-methoxyphenoxy)phenyl]propionate hydrochloride 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 甲醇 、 水 为溶剂， 反应 2.67h， 以55%的产率得到methyl 3-[3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)phenyl]propionate
  参考文献：
  名称：

  Thyroid Receptor Ligands. 6. A High Affinity “Direct Antagonist” Selective for the Thyroid Hormone Receptor

  摘要：

  A new high-affinity thyroid hormone antagonist 6 with druglike properties was designed and synthesized. The compound behaved as an antagonist in a cell transactivation assay, and in a first in vivo experiment in rats.

  DOI：

  10.1021/jm060521i

文献信息

• Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
  申请人：Malm Johan

  公开号：US20050107347A1

  公开（公告）日：2005-05-19

  This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.

  本发明涉及一种新型化合物，其是甲状腺受体配体，优选为拮抗剂，并涉及使用此类化合物治疗心脏和代谢性疾病的方法，例如心律失常、甲状腺毒症、亚临床甲状腺功能亢进和肝脏疾病。
• PRIME RING SUBSTITUTED THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS
  申请人：KARO BIO AB

  公开号：EP1499578A2

  公开（公告）日：2005-01-26
• US7279593B2
  申请人：——

  公开号：US7279593B2

  公开（公告）日：2007-10-09
• [EN] PRIME RING SUBSTITUTED THYROID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CARDIAC AND METABOLIC DISORDERS<br/>[FR] ANTAGONISTES PRINCIPALES DU RECEPTEUR DE LA THYROIDE DE SUBSTITUTION DESTINES AU TRAITEMENT DE TROUBLES CARDIAQUES OU METABOLIQUES
  申请人：KAROBIO AB

  公开号：WO2003018515A2

  公开（公告）日：2003-03-06

  This invention relates to novel compounds according to the general formula (I) or a pharmaceutically acceptable salt thereof, which are thyroid receptor ligands, preferably antagonists and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyroidism and liver diseases.